Pacira BioSciences Reports Third Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/30/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
Pacira Pharmaceuticals (PCRX) PT Raised to $62 at BMO Capital
November 5, 2021 6:49 AM EDTBMO Capital analyst Gary Nachman raised the price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $62.00 (from $60.00) while maintaining a Market Perform rating.
The analyst commented, "3Q Exparel sales preannounced 10/11 had been weaker-than-expected from continued COVID headwinds, but PCRX's optimistic in recovering procedure trends... More
Pacira Pharma (PCRX) Tops Q3 EPS by 7c
November 3, 2021 8:06 AM EDTPacira Pharma (NASDAQ: PCRX) reported Q3 EPS of $0.72, $0.07 better than the analyst estimate of $0.65. Revenue for the quarter came in at $127.7 million versus the consensus estimate of $130.38 million.
For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.
... More